Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma (HCC) since 2007 and numerous studies have investigated the role of markers involved in the angiogenesis process at both the expression and genetic level and clinical aspect. What results have ten years of research produced? Several clinical and biological markers are associated with prognosis. The most interesting clinical parameters are adverse events, Barcelona Clinic Liver Cancer stage, and macroscopic vascular invasion, while several single nucleotide polymorphisms and plasma angiopoietin-2 levels represent the most promising biological biomarkers. A recent pooled analysis of two phase III randomized trials showed that the neutrophil-to-lymphocyte ratio, etiology and extra-hepatic spread are predictive factors of response to sorafenib, but did not identify any predictive biological markers. After 10 years of research into sorafenib there are still no validated prognostic or predictive factors of response to the drug in HCC. The aim of the present review was to summarize 10 years of research into sorafenib, looking in particular at the potential of associated clinical and biological markers to predict its efficacy in patients with advanced HCC.

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? / Marisi, Giorgia; Cucchetti, Alessandro; Ulivi, Paola; Canale, Matteo; Cabibbo, Giuseppe; Solaini, Leonardo; Foschi, Francesco G; De Matteis, Serena; Ercolani, Giorgio; Valgiusti, Martina; Frassineti, Giovanni L; Scartozzi, Mario; Gardini, Andrea Casadei. - In: WORLD JOURNAL OF GASTROENTEROLOGY. - ISSN 1007-9327. - 24:(2018), pp. 4152-4163. [10.3748/wjg.v24.i36.4152]

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

Scartozzi, Mario;Gardini, Andrea Casadei
2018

Abstract

Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma (HCC) since 2007 and numerous studies have investigated the role of markers involved in the angiogenesis process at both the expression and genetic level and clinical aspect. What results have ten years of research produced? Several clinical and biological markers are associated with prognosis. The most interesting clinical parameters are adverse events, Barcelona Clinic Liver Cancer stage, and macroscopic vascular invasion, while several single nucleotide polymorphisms and plasma angiopoietin-2 levels represent the most promising biological biomarkers. A recent pooled analysis of two phase III randomized trials showed that the neutrophil-to-lymphocyte ratio, etiology and extra-hepatic spread are predictive factors of response to sorafenib, but did not identify any predictive biological markers. After 10 years of research into sorafenib there are still no validated prognostic or predictive factors of response to the drug in HCC. The aim of the present review was to summarize 10 years of research into sorafenib, looking in particular at the potential of associated clinical and biological markers to predict its efficacy in patients with advanced HCC.
2018
24
4152
4163
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? / Marisi, Giorgia; Cucchetti, Alessandro; Ulivi, Paola; Canale, Matteo; Cabibbo, Giuseppe; Solaini, Leonardo; Foschi, Francesco G; De Matteis, Serena; Ercolani, Giorgio; Valgiusti, Martina; Frassineti, Giovanni L; Scartozzi, Mario; Gardini, Andrea Casadei. - In: WORLD JOURNAL OF GASTROENTEROLOGY. - ISSN 1007-9327. - 24:(2018), pp. 4152-4163. [10.3748/wjg.v24.i36.4152]
Marisi, Giorgia; Cucchetti, Alessandro; Ulivi, Paola; Canale, Matteo; Cabibbo, Giuseppe; Solaini, Leonardo; Foschi, Francesco G; De Matteis, Serena; Ercolani, Giorgio; Valgiusti, Martina; Frassineti, Giovanni L; Scartozzi, Mario; Gardini, Andrea Casadei
File in questo prodotto:
File Dimensione Formato  
WJG-24-4152.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 1.74 MB
Formato Adobe PDF
1.74 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1177410
Citazioni
  • ???jsp.display-item.citation.pmc??? 65
  • Scopus 129
  • ???jsp.display-item.citation.isi??? 126
social impact